ARTICLE | Clinical News
Marqibo vincristine regulatory update
July 4, 2011 7:00 AM UTC
Talon said it will delay the submission of an NDA to FDA to 3Q11 from the end of June for its cancer candidate Marqibo vincristine sulfate. Talon is seeking accelerated approval to treat Philadelphia ...